The $4 Billion Problem in Lyme Diagnostics with Aces Diagnostics скачать в хорошем качестве

The $4 Billion Problem in Lyme Diagnostics with Aces Diagnostics

In this episode of Diagnosing Dx, I’m joined by ⁠Tammy Crawford⁠, Chief Executive Officer, and ⁠Holly Ahern⁠, Chief Scientific Officer at ⁠Aces Diagnostics⁠, a company building what could become the first highly accurate test across all stages of Lyme disease. We explore why early Lyme is so often missed, the myth of the bullseye rash, and the structural gaps in today’s testing pathway. Tammy and Holly explain how their personal experiences shaped Aces Diagnostics’ mission and how they’re approaching the problem with a more rigorous, data-driven framework built for real-world adoption. This conversation is a grounded look at what it takes to restore confidence in infectious disease diagnostics and why more reliable testing could transform both patient outcomes and healthcare economics. Key takeaways: 🔹 Why current Lyme diagnostics frequently miss early-stage disease 🔹 How combining multiple biomarkers improves diagnostic accuracy 🔹 The role of machine learning in interpreting complex immune signatures 🔹 Why FDA approval is essential for trust, adoption, and scale 🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics. #LymeDisease #LymeDiseaseAwareness #LymeDiseaseDiagnosis #InfectiousDisease #Diagnostics #MedicalDiagnostics #HealthcareInnovation #AIinHealthcare #MachineLearningInMedicine #Biomarkers #PrecisionMedicine #MedTech #FDAApproval #ClinicalInnovation #FutureOfDiagnostics